re: Ann: Response to Peabody's Further Pr... the decision not to take the $15 was an absolute slap in the face for investors...price has nearly halved...what a disgrace!!
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%